162 related articles for article (PubMed ID: 21745011)
1. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.
Picker A; Jackson DB
Expert Rev Mol Diagn; 2011 Jul; 11(6):567-77. PubMed ID: 21745011
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
3. The search for optimal response prediction in cancer leads to a personalized approach.
Van Cutsem E; Ciardiello F
Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
[No Abstract] [Full Text] [Related]
4. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
[TBL] [Abstract][Full Text] [Related]
6. Predicting drug response based on gene expression.
Robert J; Vekris A; Pourquier P; Bonnet J
Crit Rev Oncol Hematol; 2004 Sep; 51(3):205-27. PubMed ID: 15331079
[TBL] [Abstract][Full Text] [Related]
7. Progress towards personalized medicine.
Bates S
Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397
[TBL] [Abstract][Full Text] [Related]
8. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy: overcoming drug resistance with clinical cancer genome.
Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
[No Abstract] [Full Text] [Related]
11. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
12. From genomic landscapes to personalized cancer management-is there a roadmap?
Swanton C; Caldas C
Ann N Y Acad Sci; 2010 Oct; 1210():34-44. PubMed ID: 20973797
[TBL] [Abstract][Full Text] [Related]
13. [Current status and problems of tailor-made medicine in anticancer therapy].
Miya T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):515-9. PubMed ID: 17431334
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
15. Molecular-based choice of cancer therapy: realities and expectations.
Imyanitov EN; Moiseyenko VM
Clin Chim Acta; 2007 Apr; 379(1-2):1-13. PubMed ID: 17306783
[TBL] [Abstract][Full Text] [Related]
16. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
17. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
18. Refocusing the war on cancer: the critical role of personalized treatment.
Potti A; Schilsky RL; Nevins JR
Sci Transl Med; 2010 Apr; 2(28):28cm13. PubMed ID: 20410527
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer: current management and opportunities for a personalized approach.
Galsky MD; Hall SJ
Mt Sinai J Med; 2010; 77(6):587-96. PubMed ID: 21105122
[TBL] [Abstract][Full Text] [Related]
20. [Front-line drug discovery system for cancer].
Mizukami T
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
